See Us Next At: Hello Tomorrow

26 October 2017 | Le Centquatre | Paris, France

Unlocking Next Generation Therapies

Using microfluidics, automation and machine learning
From regenerating damaged tissues to leveraging the immune system to fight cancer, new waves of therapies are about to break through to patients worldwide. Complex, cell-based assays are the workhorses behind these breakthroughs. We work at the frontier of microfluidics, automation and machine learning to turbocharge these complex-cell based assays, and accelerate the advent of these next generation therapies.

Our Three Part Solution

Advanced Therapies Require Advanced Technology

thousand experiments

Times Less Materials

Times Faster

Current Operations

our platform relieves key bottlenecks in multiple areas
cell therapy - optimizing cell manufacturing operational
Immuno-oncology - discovery, QC & release testing validating
Personalized Medicine in development


Core Team

inter-disciplinary experience drawn from around the world
Drew Titmarsh, PHD
ceo & co-founder

Brief Bio

Drew Titmarsh is a trained chemical and biological engineer who designs and builds technology to understand the processes that drive the regeneration of human cells and tissue. He is the core developer of the microbioreactor array technology which is the workhorse platform of Scaled Biolabs. He has coordinated multidisciplinary projects at the Australian Institute for Bioengineering and Nanotechnogy (Brisbane, Australia), and the Institute for Medical Biology, A*STAR (Singapore) in the areas of tissue engineering and regenerative medicine.

Brendan Griffen, PHD
cto & co-founder

Brief Bio

Brendan Griffen has lead several large, data-driven projects in the fields of computational cosmology, astrophysics and theoretical physics at leading institutes across the USA, UK, Germany and Australia. Having completed his postdoctoral research at MIT's Kavli Institute For Astrophysics & Space Research, he now builds the analytical backend behind Scaled Biolabs' high-throughput wet lab platform employing tools such as statistical methods, control systems, optimization, computer vision and machine learning.

Prof. Justin Cooper-White, PHD
cso & co-founder

Brief Bio

Professor Justin Cooper-White is a global leader in using engineering to solve problems in biology. In addition to holding the position of The Australian Institute of Bioengineering & Nanotechnology Group Leader, Professor Cooper-White is Director of the Australian National Fabrication Facility-Queensland Node and is one of only 13 CSIRO Office of the Chief Executive Science Leaders in Australia. He is a past President of both the Australasian Society for Biomaterials and Tissue Engineering and the Australian Society of Rheology and has previously served as an Associate Dean at the UQ Faculty of Engineering, Architecture and Information Technology.


Thoughts & News

A window into our approach from our blog and our latest news

Scaled Wins CIRM DISC-02 Grant

June 29, 2017 We're excited to announce that CIRM, California's stem cell agency, awarded us with a 2-year, ~$700k DISC-02 discovery grant. Together with collaborators at The Scripps Research Institute, we will deploy our technology to produce optimized, clinical grade manufacturing processes for dopaminergic neuron cells with the goal of treating patients with Parkinson's disease. Read More

Subscribe to our monthly newsletter

Opt out at any time.

Our Partners

partners who share our vision

Please contact us for investor enquries.


Contact

please reach out